Next Generation Antibody Therapeutics Market (2nd Edition): Industry Trends and Global Forecasts, Till 2035 - Distribution by Drug, Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, Key Geographical Regions and Leading Players

The next generation antibody therapeutics market is estimated to grow from USD 5.45 billion in the current year to USD 5.76 billion by 2035, at a CAGR of 1%
during the forecast period, till 2035.

Next Generation Antibody Therapeutics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Drugs

Adcetris
Kadcyla
ELZONRIS
Besponsa
LYMPHIR
Fibromun
Nidlegy
Iomab-B
TLX 591

Type of Novel Antibody

Radioisotope Immunoconjugates
Immunocytokines
Immunotoxins

Target Indication

Previously Untreated Systemic Anaplastic Large Cell Lymphoma (SALCL) or other CD30-expressing Peripheral T-cell Lymphomas (PTCL)
Classical Hodgkin Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or
CD30-expressing Mycosis Fungoides (MF)
Diffuse Large B-cell Lymphoma
Relapsed or Refractory B-cell precursor Acute
Lymphoblastic Leukemia
HER2-positive breast cancer
Blastic Plasmacytoid Dendritic Cell Neoplasm
Locally Advanced, Melanoma / Stage III B / C Melanoma
Relapsed or Refractory Cutaneous T-cell Lymphoma
Relapsed / Refractory Acute Myeloid
Leukemia
Metastatic Castration-resistant Prostate Cancer
Soft Tissue Sarcoma

Type of Therapy

Combination Therapy
Monotherapy

Route of Administration

Intratumoral
Intravenous

Geographical Regions

North America
Europe
Asia-Pacific
Middle East and Africa

NOVEL ANTIBODY THERAPIES MARKET: GROWTH AND TRENDS

Antibodies, or immunoglobulins, are proteins generated by the immune system that identify and attach to particular antigen markers on cells or tissues, acting as the primary defense against various ailments. Utilizing the accuracy of antibody-antigen interactions, innovative antibody treatments have shown considerable promise in enhancing patient results. In recent years, numerous innovative antibody treatments received approval from the USFDA, signifying notable progress in the treatment of a range of illnesses, such as metabolic disorders, cardiovascular issues, cancer, and rare diseases. These authorizations demonstrate the effectiveness of biotechnological methods in tackling significant healthcare issues and underscore the role of antibody therapies in contemporary medicine. Increased funding and investments, along with partnership initiatives, are vital for the research and development of new antibodies targeting various disorders. Moreover, numerous advanced technologies are transforming the identification and development of new therapies, fundamentally changing treatment approaches.

NOVEL ANTIBODY THERAPIES MARKET: KEY INSIGHTS

The report delves into the current state of the global novel antibody therapies market and identifies potential growth opportunities within industry. Some key findings from the report include:

Over 70 radioisotope immunoconjugates are approved / being investigated across different stages of development for the treatment of various diseases; of these, >80% of the therapies are in early-stages of development.

Close to 70% of the monotherapies can be administered intravenously; of these, majority (96%) of the therapies are under clinical stages of development.
Over 35 immunocytokines are currently approved / being investigated across various stages of development for the treatment of various diseases; of these, nearly 60% of the therapies are in early-stages of development.
Presently, over 45% of immunocytokines in early stages of development are in conjugation with IL-2 and IL-15 types of cytokine; of these, majority (80%) of the therapies can be administered as combination therapy.
Nearly 60 immunotoxins are currently approved / being investigated across different stages of development for the treatment of various diseases; of these, more than 45% of the therapies are in early-stages of development.
Presently, nearly 80% of the late-stage immunotoxins (phase II and phase II / III) are administered via injections; further, 56% immunotoxins are in conjugation with microbial toxins.
Most of the trials were registered in 2024; notably, a significant proportion (72%) of the total trials are currently recruiting patients for the investigation of novel antibody therapies.
The growing scientific literature highlights the active involvement of stakeholders in the research and development of novel antibody therapies; close to 35% of the articles were published in the previous year.
Majority of the patent assignees are non-industry players; however, over the past few years, the contribution of industry players in the patent filing activity has also increased.

Close to 20% deals inked in this domain are supply agreements; of these, 44% agreements were signed in 2022 in order to address the growing demand for novel antibodies.
Using our proprietary forecast model, we estimated the current size of the global novel antibody therapies market, taking into consideration the historical trends, data and inputs obtained from exhaustive research.

Currently, the global novel antibody therapies market is dominated by drugs that are intended to target HER2-positive breast cancer, followed by classical Hodgkin lymphoma.

NOVEL ANTIBODY THERAPIES MARKET: KEY SEGMENTS

Adcetris Drug Captures the Largest Share in the Next Generation Antibody Therapeutics Market

Currently, Adcetris holds the higher market share of close to 45% due to its early approvals and proven effectiveness in hematologic cancers. LYMPHIR is expected to expand at an increased CAGR of 18% throughout the forecast period.

Immunotoxins Segment Holds the Majority of the Next Generation Antibody Therapeutics Market Share

The higher share of immunotoxins segment in the current year can be attributed to their superior targeted cytotoxicity and effectiveness against resistant cancer cells, as per next generation antibody therapeutics market forecast. Further, the immunocytokines sector is expected to exhibit the greatest growth potential, of over 40%, throughout the forecast period.

HER2-PBC Hold the Largest Share in the Next Generation Antibody Therapeutics Market

In the present year, HER2-PB captures a significant market share of nearly 45% in novel antibody therapies, driven by the growing incidence of HER2-positive breast cancer and the heightened use of targeted treatments that lead to substantial enhancements in patient outcomes and survival rates. The segment for relapsed or refractory cutaneous T-cell lymphoma is expected to exhibit the greatest growth potential of nearly 20% throughout the forecast period.

Monotherapy Dominates Next Generation Antibody Therapies Industry

Monotherapy segment holds most of the market share in the current year owing to its ability to provide highly specific targeting with fewer side effects. The combination therapy segment is likely to show the highest growth potential of close to 45%, during the forecast period.

Intravenous Route of Administration Dominates Next Generation Antibody Therapeutics Market Share

Currently, intravenous route of administration, the intravenous method dominates the market due to its capacity to provide a quick onset of action and improved bioavailability needed for effectively delivering large antibodies. The intratumoral method of delivery is expected to expand at a higher CAGR, fueled by its capacity to attain greater local drug levels, reduce systemic toxicity, and enhance treatment effectiveness

North America is Likely to Propel in the Next Generation Antibody Therapeutics Market in the Coming Years

According to our next generation antibody therapeutics market report, North America is likely to capture the majority (64%) of the market share in the current year, and this trend is unlikely to change in the future. This can be attributed to the strong healthcare system, innovative platforms for developing new antibody treatments, and a significant emphasis on personalized care, positioning this region at the forefront of novel antibody treatments.

Example Players in the Next Generation Antibody Therapeutics Market

Actinium Pharmaceuticals
Pfizer
Philogen
Roche
Telix Pharmaceuticals
Y-mAbs Therapies

NOVEL ANTIBODY THERAPIES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the novel antibody therapies market, focusing on key market segments, including [A] drug, [B] type of novel antibody, [C] target indication, [D] type of therapy, [E] route of administration and [F] leading players.
Market Landscape 1: A detailed assessment of the current market landscape of radioisotope immunoconjugates, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of therapy, [C] route of administration, [D] dosing frequency, [E] type of radioisotope, [F] mode of administration, [G] mechanism of action [H] therapeutic area, [I] year of establishment, [J] company size, [K] location of headquarters, [L] type of developer and [M] most active players.
Market Landscape 2: A detailed assessment of the current market landscape of immunocytokines, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of cytokine, [C] type of therapy, [D] dosing frequency, [E] mechanism of action, [F] mode of administration, [G] type of antigen / format, [H] route of administration [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
Market Landscape 3: A detailed assessment of the current market landscape of immunotoxins, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of toxin, [C] dosing frequency, [D] type of therapy, [E] mode of administration, [F] type of target, [G] mechanism of action, [H] route of administration, [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
Company Profiles: In-depth profiles of prominent players based in regions, namely North America, Europe and Asia-Pacific that are currently involved in the engaged in the development of novel antibody therapies. Each profile features [A] a brief overview of the company, [B] its financial information, [C] details on its drug portfolio, [D] recent developments and an [E] informed future outlook.
Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating different novel antibody therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] study design, patient gender, [F] type of sponsor / collaborator, [G] most active industry and [H] geographical distribution.
Publication Analysis: A detailed review of various peer-reviewed, scientific articles related to research on novel antibody therapies, based on relevant parameters, such as [A] year of publication, [B] type of publication, [C] popular publisher and [D] key journal.
Patent Analysis: in-depth analysis of various patents that have been filed / granted for novel antibody therapies, taking into consideration parameters, such as [A] publication year, [B] type of patent, [C] type of applicant, [D] application year, [E] patent jurisdiction, patent age, [F] CPC symbols, [G] leading players.
Partnerships and Collaborations An insightful analysis of the partnerships and collaborations established in gene therapy, non viral vector and viral vector manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
Big Pharma Players: An analysis of big pharma players engaged in the field of novel antibody therapies, based on several relevant parameters, such as [A] developer strength, [B] portfolio strength, and [C] portfolio diversity.
Recent Expansions: An analysis of the recent expansions undertaken by various companies in order to augment their respective capabilities related to viral vector and non viral vector manufacturing, based on several parameters, such as [A] year of expansion, [B] type of expansion, [C] type of vector, [D] application area and [E] geographical location of the expansion.
Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of gene therapy, non viral vector and viral vector manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What is the current global capacity of developers?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs Covering All Analytical Modules
Up to 15% Complimentary Content Customization
In-Depth Report Walkthrough with the Research Team
Complimentary Report Update if the Report is 6+ Months Old

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Research Assumptions
2.1.1. Market Landscape and Market Trends
2.1.2. Market Forecast and Opportunity Analysis
2.1.3. Comparative Analysis
2.2. Database Building
2.2.1. Data Collection
2.2.2. Data Validation
2.2.3. Data Analysis
2.3. Project Methodology
2.3.1. Project Commencement
2.3.2. Secondary Research
2.3.2.1. Annual Reports
2.3.2.2. Academic Research Papers
2.3.2.3. Company Websites
2.3.2.4. Investor Presentations and Regulatory Filings
2.3.2.5. White Papers
2.3.2.6. Industry Publications
2.3.2.7. Conferences and Seminars
2.3.2.8. Government Portals
2.3.2.9. Media and Press Releases
2.3.2.10. Newsletters
2.3.2.11. Industry and Paid Databases
2.3.2.12. Roots Proprietary Databases
2.3.3. Primary Research
2.3.4. Data Analysis and Interpretation
2.3.5. Market Forecast and Validation
2.3.6. Report Compilation
2.4. Research Ethics and Integrity
2.5. Analytical Tools and Databases
2.6. Robust Quality Control Framework

3. MARKET DYNAMICS

3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Extrapolation
3.3.5. Convergence
3.3.6. Sensitivity Analysis
3.3.7. Scenario Planning
3.3.8. Data Visualization
3.3.9. Time Series Analysis
3.3.10. Forecast Error Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Economic Factors
3.4.3. Competitive Landscape
3.4.4. Government Regulations and Policies
3.4.5. R&D Investment
3.4.6. Technological Factors
3.4.7. Industry Consolidation
3.4.8. Supply Chain
3.4.9. Market Access
3.4.10. Pandemics / Unforeseen Disruptions Impact

4. MACRO-ECONOMIC INDICATORS

4.1. Market Dynamics
4.1.1. Time Period
4.1.1.1. Historical Trends
4.1.1.2. Current and Forecasted Estimates
4.1.2. Currency Coverage
4.1.2.1. Overview of Major Currencies Affecting the Market
4.1.2.2. Impact of Currency Fluctuations on the Industry
4.1.3. Foreign Exchange Impact
4.1.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.1.3.2. Strategies for Mitigating Foreign Exchange Risk
4.1.4. Recession
4.1.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.1.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.1.5. Inflation
4.1.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.1.5.2. Potential Impact of Inflation on the Market Evolution
4.1.6. Other Indicators
4.1.6.1. War Impact Analysis
4.1.6.2. Cross-border Dynamics
4.1.6.3. Consumer Spendings and Gross Domestic Product
4.1.6.4. Stock Market Performance

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. An Overview of Novel Antibody Therapies
6.2. Therapeutic Antibodies: Developmental Approaches
6.2.1. Novel Antibody Therapies: Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
6.2.1.1. Mechanism of Action of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
6.2.1.2. Advantages of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
6.2.1.3. Disadvantages of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
6.2.2. Novel Antibody Therapies: TCR like Antibodies
6.2.2.1. Mechanism of Action of TCR like Antibodies
6.2.2.2. Advantages of TCR like Antibodies
6.2.2.3. Disadvantages of TCR like Antibodies
6.2.3. Novel Antibody Therapies: Radioisotope Immunoconjugates
6.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
6.2.3.2. Advantages of Radioisotope Immunoconjugates
6.2.3.3. Disadvantages of Radioisotope Immunoconjugates
6.2.4. Novel Antibody Therapies: Immunotoxins
6.2.4.1. Mechanism of Action of Immunotoxins
6.2.4.2. Advantages of Immunotoxins
6.2.4.3. Disadvantages of Immunotoxins
6.2.5. Novel Antibody Therapies: Intracellular Antibody
6.2.5.1. Mechanism of Action of Intracellular Antibody
6.2.5.2. Advantages of Intracellular Antibody
6.2.5.3. Disadvantages of Intracellular Antibody
6.2.6. Novel Antibody Therapies: Immunocytokines
6.2.6.1. Mechanism of Action of Immunocytokines
6.2.6.2. Advantages of Immunocytokines
6.2.6.3. Disadvantages of Immunocytokines
6.3. Future Perspectives

7. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (RADIOISOTOPE IMMUNOCONJUGATES)

7.1. Chapter Overview
7.2. Market Landscape: Radioisotope Immunoconjugates
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Therapy
7.2.3. Analysis by Route of Administration
7.2.4. Analysis by Dosing Frequency
7.2.5. Analysis by Type of Radioisotope
7.2.6. Analysis by Mode of Administration
7.2.7. Analysis by Mechanism of Action
7.2.8. Analysis by Therapeutic Area
7.3. Developer Landscape: Radioisotope Immunoconjugates
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Type of Developer
7.3.5. Most Active Players: Analysis by Number of Therapies

8. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (IMMUNOCYTOKINES)

8.1. Chapter Overview
8.2. Market Landscape: Immunocytokines
8.2.1. Analysis by Stage of Development
8.2.2. Analysis by Type of Cytokine
8.2.3. Analysis by Type of Therapy
8.2.4. Analysis by Dosing Frequency
8.2.5. Analysis by Mechanism of Action
8.2.6. Analysis by Mode of Administration
8.2.7. Analysis by Type of Antigen / Format
8.2.8. Analysis by Route of Administration
8.2.9. Analysis by Therapeutic Area
8.3. Developer Landscape: Immunocytokines
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Most Active Players: Analysis by Number of Therapies

9. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (IMMUNOTOXINS)

9.1. Chapter Overview
9.2. Market Landscape: Immunotoxins
9.2.1. Analysis by Stage of Development
9.2.2. Analysis by Type of Toxin
9.2.3. Analysis by Dosing Frequency
9.2.4. Analysis by Type of Therapy
9.2.5. Analysis by Mode of Administration
9.2.6. Analysis by Type of Target
9.2.7. Analysis by Mechanism of Action
9.2.8. Analysis by Route of Administration
9.2.9. Analysis by Therapeutic Area
9.3. Developer Landscape: Immunotoxins
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Type of Developer
9.3.5. Most Active Players: Analysis by Number of Therapies

10. NOVEL ANTIBODY DEVELOPERS

10.1. Chapter Overview
10.1.1. Actinium Pharmaceuticals
10.1.1.1. Company Overview
10.1.1.2. Management Team
10.1.1.3. Contact Details
10.1.1.4. Drug Portfolio
10.1.1.5. Recent Developments and Future Outlook
10.1.2. Pfizer
10.1.2.1. Company Overview
10.1.2.2. Management Team
10.1.2.3. Contact Details
10.1.2.4. Operating Business Segments
10.1.2.5. Financial Information
10.1.2.6. Drug Portfolio
10.1.2.7. Recent Developments and Future Outlook
10.1.3. Philogen
10.1.3.1. Company Overview
10.1.3.2. Management Team
10.1.3.3. Contact Details
10.1.3.4. Financial Information
10.1.3.5. Drug Portfolio
10.1.3.6. Recent Developments and Future Outlook
10.1.4. Roche
10.1.4.1. Company Overview
10.1.4.2. Management Team
10.1.4.3. Contact Details
10.1.4.4. Operating Business Segments
10.1.4.5. Financial Information
10.1.4.6. Drug Portfolio
10.1.4.7. Recent Developments and Future Outlook
10.1.5. Telix Pharmaceuticals
10.1.5.1. Company Overview
10.1.5.2. Management Team
10.1.5.3. Contact Details
10.1.5.4. Financial Information
10.1.5.5. Drug Portfolio
10.1.5.6. Recent Developments and Future Outlook
10.1.6. Y-mAbs Therapeutics
10.1.6.1. Company Overview
10.1.6.2. Management Team
10.1.6.3. Contact Details
10.1.6.4. Financial Information
10.1.6.5. Drug Portfolio
10.1.6.6. Recent Developments and Future Outlook

11. CLINICAL TRIAL ANALYSIS

11.1. Analysis Methodology and Key Parameters
11.2. Analysis by Trial Registration Year
11.3. Analysis by Trial Status
11.4. Analysis by Trial Registration Year and Trial Status
11.5. Analysis of Patients Enrolled by Trial Registration Year
11.6. Analysis of Patients Enrolled by Trial Status
11.7. Analysis by Trial Phase
11.8. Analysis by Study Design
11.9. Analysis by Target Patient Population
11.9.1. Analysis by Patient Gender
11.9.2. Analysis by Type of Sponsor / Collaborator
11.9.3. Most Active Industry Players: Analysis by Number of Trials
11.9.4. Analysis of Trials and Number of Patients Enrolled

12. PUBLICATION ANALYSIS

12.1. Analysis Methodology and Key Parameters
12.2. Novel Antibody Therapies: Publication Analysis
12.2.1. Analysis by Year of Publication
12.2.2. Analysis by Type of Publication
12.2.3. Analysis by Most Popular Publisher
12.2.4. Key Journals: Analysis by Number of Publications
12.2.5. Key Journals: Analysis by Impact Factor

13. PATENT ANALYSIS

13.1. Analysis Methodology and Key Parameters
13.2. Novel Antibody Therapies: Patent Analysis
13.2.1. Analysis by Publication Year
13.2.2. Analysis by Type of Patent
13.2.3. Analysis of Granted Patents and Patent Applications by Year
13.2.4. Analysis by Type of Applicant
13.2.5. Analysis by Application Year
13.2.6. Analysis by Patent Jurisdiction
13.2.7. Analysis by Patent Age
13.2.8. Leading Industry Players: Analysis by Number of Patents
13.2.9. Leading Non-Industry Players: Analysis by Number of Patents
13.2.10. Leading Individual Assignees: Analysis by Number of Patents
13.2.11. Patent Benchmarking: Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
13.2.12. Patent Benchmarking: Analysis of Leading Industry Players by Patent Characteristics (CPC Codes)
13.2.13. Patent Valuation: Analysis Methodology and Parameters
13.2.14. Patent Valuation: Analysis by Relative Valuation

14. PARTNERSHIPS AND COLLABORATIONS

14.1. Chapter Overview
14.2. Partnership Models
14.3. Novel Antibody Therapeutics: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Most Popular Drug: Analysis by Number of Partnerships
14.3.5. Analysis by Types of Novel Antibody
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Therapeutic Area
14.3.9. Analysis by Therapeutic Area and Type of Partnership
14.3.10. Analysis by Geography
14.3.10.1. Local and International Agreements
14.3.10.2. Intracontinental and Intercontinental Agreements

15. BIG PHARMA PLAYERS

15.1. Analysis Methodology and Key Parameters
15.2. List of Big Pharma Players in Novel Antibody Therapies Domain
15.3. Scoring Criteria for Key Parameters
15.3.1. Analysis by Developer Strength
15.3.2. Analysis by Portfolio Strength
15.3.3. Analysis by Portfolio Diversity
15.3.4. Benchmarking: Spider Web Analysis
15.3.5. Benchmarking: Harvey Ball Analysis
15.3.6. Benchmarking: Wind Rose Chart

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges

17. GLOBAL NOVEL ANTIBODY THERAPIES MARKET

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Novel Antibody Therapies Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
17.4. Multivariate Scenario Analysis
17.4.1. Conservative Scenario
17.4.2. Optimistic Scenario
17.5. Key Market Segmentations

18. NOVEL ANTIBODY THERAPIES MARKET, BY DRUGS

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Novel Antibody Therapies Market: Distribution by Drugs
18.3.1. Novel Antibody Therapies Market for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.2. Novel Antibody Therapies Market for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.3. Novel Antibody Therapies Market for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.4. Novel Antibody Therapies Market for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.5. Novel Antibody Therapies Market for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.6. Novel Antibody Therapies Market for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.7. Novel Antibody Therapies Market for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.8. Novel Antibody Therapies Market for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.3.9. Novel Antibody Therapies Market for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation

19. NOVEL ANTIBODY THERAPIES MARKET, BY TYPE OF NOVEL ANTIBODY

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Novel Antibody Therapies Market: Distribution by Type of Novel Antibody
19.3.1. Novel Antibody Therapies Market for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
19.3.2. Novel Antibody Therapies Market for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
19.3.3. Novel Antibody Therapies Market for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation

20. NOVEL ANTIBODY THERAPIES MARKET, BY TARGET INDICATION

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Novel Antibody Therapies Market: Distribution by Target Indication
20.3.1. Novel Antibody Therapies Market for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.2. Novel Antibody Therapies Market for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.3. Novel Antibody Therapies Market for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.4. Novel Antibody Therapies Market for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.5. Novel Antibody Therapies Market for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.6. Novel Antibody Therapies Market for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.7. Novel Antibody Therapies Market for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.8. Novel Antibody Therapies Market for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.9. Novel Antibody Therapies Market for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.10. Novel Antibody Therapies Market for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.11. Novel Antibody Therapies Market for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.3.12. Novel Antibody Therapies Market for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation

21. NOVEL ANTIBODY THERAPIES MARKET, BY TYPE OF THERAPY

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Novel Antibody Therapies Market: Distribution by Type of Therapy
21.3.1. Novel Antibody Therapies Market for Monotherapy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
21.3.2. Novel Antibody Therapies Market for Combination Therapy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation

22. NOVEL ANTIBODY THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Novel Antibody Therapies Market: Distribution by Route of Administration
22.3.1. Novel Antibody Therapies Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
22.3.2. Novel Antibody Therapies Market for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation

23. NOVEL ANTIBODY THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Novel Antibody Therapies Market: Distribution by Geographical Regions
23.3.1. Novel Antibody Therapies Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.1.1. Novel Antibody Therapies Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.1.2. Novel Antibody Therapies Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2. Novel Antibody Therapies Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2.1. Novel Antibody Therapies Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2.2. Novel Antibody Therapies Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2.3. Novel Antibody Therapies Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2.4. Novel Antibody Therapies Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.2.5. Novel Antibody Therapies Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.3. Novel Antibody Therapies Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.3.1. Novel Antibody Therapies Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.3.2. Novel Antibody Therapies Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.3.3. Novel Antibody Therapies Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.3.4. Novel Antibody Therapies Market in New Zealand, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.4. Novel Antibody Therapies Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.4.1. Novel Antibody Therapies Market in Egypt, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.4.2. Novel Antibody Therapies Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.4.3. Novel Antibody Therapies Market in Iraq, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3.4.4. Novel Antibody Therapies Market in Morocco, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.4. Novel Antibody Therapies Market, By Geographical Regions: Market Dynamics Assessment
23.4.1. Market Movement Analysis
23.4.2. Penetration-Growth (P-G) Matrix
23.5. Data Triangulation and Validation

24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

24.1. Novel Antibody Therapies Market in North America: Distribution by Drugs
24.1.1. Novel Antibody Therapies Market in North America for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.2. Novel Antibody Therapies Market in North America for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.3. Novel Antibody Therapies Market in North America for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.4. Novel Antibody Therapies Market in North America for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.5. Novel Antibody Therapies Market in North America for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.6. Novel Antibody Therapies Market in North America for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.7. Novel Antibody Therapies Market in North America for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.8. Novel Antibody Therapies Market in North America for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.1.9. Novel Antibody Therapies Market in North America for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.2. Novel Antibody Therapies Market in North America: Distribution by Type of Novel Antibody
24.2.1. Novel Antibody Therapies Market in North America for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.2.2. Novel Antibody Therapies Market in North America for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.2.3. Novel Antibody Therapies Market in North America for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3. Novel Antibody Therapies Market in North America: Distribution by Target Indication
24.3.1. Novel Antibody Therapies Market in North America for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.2. Novel Antibody Therapies Market in North America for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.3. Novel Antibody Therapies Market in North America for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.4. Novel Antibody Therapies Market in North America for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.5. Novel Antibody Therapies Market in North America for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.6. Novel Antibody Therapies Market in North America for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.7. Novel Antibody Therapies Market in North America for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.8. Novel Antibody Therapies Market in North America for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.9. Novel Antibody Therapies Market in North America for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.10. Novel Antibody Therapies Market in North America for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.11. Novel Antibody Therapies Market in North America for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3.12. Novel Antibody Therapies Market in North America for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035))
24.4. Novel Antibody Therapies Market in North America: Distribution by Type of Therapy
24.4.1. Novel Antibody Therapies Market in North America for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.4.2. Novel Antibody Therapies Market in North America for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.5. Novel Antibody Therapies Market in North America: Distribution by Route of Administration
24.5.1. Novel Antibody Therapies Market in North America for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.5.2. Novel Antibody Therapies Market in North America for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25. MARKET OPPORTUNITY ANALYSIS: EUROPE

25.1. Novel Antibody Therapies Market in Europe: Distribution by Drugs
25.1.1. Novel Antibody Therapies Market in Europe for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.2. Novel Antibody Therapies Market in Europe for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.3. Novel Antibody Therapies Market in Europe for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.4. Novel Antibody Therapies Market in Europe for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.5. Novel Antibody Therapies Market in Europe for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.6. Novel Antibody Therapies Market in Europe for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.7. Novel Antibody Therapies Market in Europe for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.8. Novel Antibody Therapies Market in Europe for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.1.9. Novel Antibody Therapies Market in Europe for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2. Novel Antibody Therapies Market in Europe: Distribution by Type of Novel Antibody
25.2.1. Novel Antibody Therapies Market in Europe for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2.2. Novel Antibody Therapies Market in Europe for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2.3. Novel Antibody Therapies Market in Europe for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3. Novel Antibody Therapies Market in Europe: Distribution by Target Indication
25.3.1. Novel Antibody Therapies Market in Europe for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.2. Novel Antibody Therapies Market in Europe for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.3. Novel Antibody Therapies Market in Europe for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.4. Novel Antibody Therapies Market in Europe for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.5. Novel Antibody Therapies Market in Europe for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.6. Novel Antibody Therapies Market in Europe for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.7. Novel Antibody Therapies Market in Europe for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.8. Novel Antibody Therapies Market in Europe for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.9. Novel Antibody Therapies Market in Europe for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.10. Novel Antibody Therapies Market in Europe for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.11. Novel Antibody Therapies Market in Europe for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3.12. Novel Antibody Therapies Market in Europe for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035))
25.4. Novel Antibody Therapies Market in Europe: Distribution by Type of Therapy
25.4.1. Novel Antibody Therapies Market in Europe for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
25.4.2. Novel Antibody Therapies Market in Europe for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
25.5. Novel Antibody Therapies Market in Europe: Distribution by Route of Administration
25.5.1. Novel Antibody Therapies Market in Europe for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.5.2. Novel Antibody Therapies Market in Europe for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

26.1. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Drugs
26.1.1. Novel Antibody Therapies Market in Asia-Pacific for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.2. Novel Antibody Therapies Market in Asia-Pacific for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.3. Novel Antibody Therapies Market in Asia-Pacific for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.4. Novel Antibody Therapies Market in Asia-Pacific for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.5. Novel Antibody Therapies Market in Asia-Pacific for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.6. Novel Antibody Therapies Market in Asia-Pacific for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.7. Novel Antibody Therapies Market in Asia-Pacific for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.8. Novel Antibody Therapies Market in Asia-Pacific for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.1.9. Novel Antibody Therapies Market in Asia-Pacific for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Type of Novel Antibody
26.2.1. Novel Antibody Therapies Market in Asia-Pacific for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2.2. Novel Antibody Therapies Market in Asia-Pacific for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2.3. Novel Antibody Therapies Market in Asia-Pacific for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Target Indication
26.3.1. Novel Antibody Therapies Market in Asia-Pacific for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.2. Novel Antibody Therapies Market in Asia-Pacific for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.3. Novel Antibody Therapies Market in Asia-Pacific for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.4. Novel Antibody Therapies Market in Asia-Pacific for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.5. Novel Antibody Therapies Market in Asia-Pacific for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.6. Novel Antibody Therapies Market in Asia-Pacific for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.7. Novel Antibody Therapies Market in Asia-Pacific for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.8. Novel Antibody Therapies Market in Asia-Pacific for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.9. Novel Antibody Therapies Market in Asia-Pacific for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.10. Novel Antibody Therapies Market in Asia-Pacific for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.11. Novel Antibody Therapies Market in Asia-Pacific for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.12. Novel Antibody Therapies Market in Asia-Pacific for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035))
26.4. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Type of Therapy
26.4.1. Novel Antibody Therapies Market in Asia-Pacific for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.4.2. Novel Antibody Therapies Market in Asia-Pacific for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.5. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Route of Administration
26.5.1. Novel Antibody Therapies Market in Asia-Pacific for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.5.2. Novel Antibody Therapies Market in Asia-Pacific for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA
27.1. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Drugs
27.1.1. Novel Antibody Therapies Market in Middle East and North Africa for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.2. Novel Antibody Therapies Market in Middle East and North Africa for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.3. Novel Antibody Therapies Market in Middle East and North Africa for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.4. Novel Antibody Therapies Market in Middle East and North Africa for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.5. Novel Antibody Therapies Market in Middle East and North Africa for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.6. Novel Antibody Therapies Market in Middle East and North Africa for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.7. Novel Antibody Therapies Market in Middle East and North Africa for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.8. Novel Antibody Therapies Market in Middle East and North Africa for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.1.9. Novel Antibody Therapies Market in Middle East and North Africa for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Type of Novel Antibody
27.2.1. Novel Antibody Therapies Market in Middle East and North Africa for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2.2. Novel Antibody Therapies Market in Middle East and North Africa for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.2.3. Novel Antibody Therapies Market in Middle East and North Africa for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Target Indication
27.3.1. Novel Antibody Therapies Market in Middle East and North Africa for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.2. Novel Antibody Therapies Market in Middle East and North Africa for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.3. Novel Antibody Therapies Market in Middle East and North Africa for PCALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.4. Novel Antibody Therapies Market in Middle East and North Africa for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.5. Novel Antibody Therapies Market in Middle East and North Africa for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.6. Novel Antibody Therapies Market in Middle East and North Africa for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.7. Novel Antibody Therapies Market in Middle East and North Africa for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.8. Novel Antibody Therapies Market in Middle East and North Africa for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.9. Novel Antibody Therapies Market in Middle East and North Africa for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.10. Novel Antibody Therapies Market in Middle East and North Africa for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.11. Novel Antibody Therapies Market in Middle East and North Africa for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.12. Novel Antibody Therapies Market in Middle East and North Africa for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035))
27.4. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Type of Therapy
27.4.1. Novel Antibody Therapies Market in Middle East and North Africa for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.4.2. Novel Antibody Therapies Market in Middle East and North Africa for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.5. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Route of Administration
27.5.1. Novel Antibody Therapies Market in Middle East and North Africa for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.5.2. Novel Antibody Therapies Market in Middle East and North Africa for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28. NOVEL ANTIBODY THERAPIES MARKET, BY LEADING PLAYERS

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Novel Antibody Therapies Market: Distribution by Leading Companies
28.4. Data Triangulation and Validation

29. TABULATED DATA30. LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Therapeutic Antibodies: Developmental Approaches
Figure 6.2 Mechanism of Action of Antibody-Directed Enzyme Prodrug Therapies
Figure 6.3 Mechanism of Action of TCR like Antibodies
Figure 6.4 Mechanism of Action of Radioisotope Immunoconjugates
Figure 6.5 Mechanism of Action of Immunotoxins
Figure 6.6 Mechanism of Action of Intracellular Antibodies
Figure 6.7 Mechanism of Action of Immunocytokines
Figure 7.1 Radioisotope Immunoconjugates: Distribution by Stage of Development
Figure 7.2 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Figure 7.3 Radioisotope Immunoconjugates: Distribution by Route of Administration
Figure 7.4 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Figure 7.5 Radioisotope Immunoconjugates: Distribution by Type of Radioisotope
Figure 7.6 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Figure 7.7 Radioisotope Immunoconjugates: Distribution by Mechanism of Action
Figure 7.8 Radioisotope Immunoconjugates: Distribution by Therapeutic Area
Figure 7.9 Radioisotope Immunoconjugate Developers: Distribution by Year of Establishment
Figure 7.10 Radioisotope Immunoconjugate Developers: Distribution by Company Size
Figure 7.11 Radioisotope Immunoconjugate Developers: Distribution by Location of Headquarters
Figure 7.12 Radioisotope Immunoconjugate Developers: Distribution by Type of Developer
Figure 7.13 Most Active Players: Distribution by Number of Therapies
Figure 8.1 Immunocytokines: Distribution by Stage of Development
Figure 8.2 Immunocytokines: Distribution by Type of Cytokine
Figure 8.3 Immunocytokines: Distribution by Type of Therapy
Figure 8.4 Immunocytokines: Distribution by Dosing Frequency
Figure 8.5 Immunocytokines: Distribution by Mechanism of Action
Figure 8.6 Immunocytokines: Distribution by Mode of Administration
Figure 8.7 Immunocytokines: Distribution by Type of Antigen / Format
Figure 8.8 Immunocytokines: Distribution by Route of Administration
Figure 8.9 Immunocytokines: Distribution by Therapeutic Area
Figure 8.10 Immunocytokine Developers: Distribution by Year of Establishment
Figure 8.11 Immunocytokine Developers: Distribution by Company Size
Figure 8.12 Immunocytokine Developers: Distribution by Location of Headquarters (Region)
Figure 8.13 Immunocytokine Developers: Distribution by Location of Headquarters (Country)
Figure 8.14 Immunocytokine Developers: Distribution by Type of Developer
Figure 8.15 Most Active Players: Distribution by Number of Therapies
Figure 9.1 Immunotoxin Therapies: Distribution by Stage of Development
Figure 9.2 Immunotoxin Therapies: Distribution by Type of Toxin
Figure 9.3 Immunotoxin Therapies: Distribution by Dosing Frequency
Figure 9.4 Immunotoxin Therapies: Distribution by Type of Therapy
Figure 9.5 Immunotoxin Therapies: Distribution by Mode of Administration
Figure 9.6 Immunotoxin Therapies: Distribution by Type of Target
Figure 9.7 Immunotoxin Therapies: Distribution by Mechanism of Action
Figure 9.8 Immunotoxin Therapies: Distribution by Route of Administration
Figure 9.9 Immunotoxin Therapies: Distribution by Therapeutic Area
Figure 9.10 Immunotoxin Developers: Distribution by Year of Establishment
Figure 9.11 Immunotoxin Developers: Distribution by Developer Size
Figure 9.12 Immunotoxin Developers: Distribution by Location of Headquarters (Region)
Figure 9.13 Immunotoxin Developers: Distribution by Location of Headquarters (Country)
Figure 9.14 Immunotoxin Developers: Distribution by Type of Developer
Figure 9.15 Most Active Players: Distribution by Number of Therapies
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.4 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 11.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 11.8 Clinical Trial Analysis: Distribution by Study Design
Figure 11.9 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 11.10 Clinical Trial Analysis: Distribution by Patient Gender
Figure 11.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.12 Most Active Players: Distribution by Number of Registered Trials
Figure 11.13 Clinical Trial Analysis: Distribution of Trials and Number of Patients Enrolled by Geography
Figure 11.14 Clinical Trial Analysis: North America: Key Insights
Figure 11.15 Clinical Trial Analysis: Europe: Key Insights
Figure 11.16 Clinical Trial Analysis: Asia-Pacific: Key Insights
Figure 11.17 Clinical Trial Analysis: Rest of the World: Key Insights
Figure 11.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 12.1 Publication Analysis: Distribution by Year of Publication
Figure 12.2 Publication Analysis: Distribution by Type of Publication
Figure 12.3 Most Popular Publisher: Distribution by Number of Publications
Figure 12.4 Key Journals: Distribution by Number of Publications
Figure 12.5 Publication Analysis: Distribution by Impact Factor
Figure 13.1 Patent Analysis: Distribution by Publication Year
Figure 13.2 Patent Analysis: Distribution by Type of Patent
Figure 13.3 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year
Figure 13.4 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 13.5 Patent Analysis: Distribution by Application Year
Figure 13.6 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Figure 13.7 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Figure 13.8 Patent Analysis: Distribution by Patent Age
Figure 13.9 Leading Industry Players: Distribution by Number of Patents
Figure 13.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 13.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 13.13 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.14 Patent Analysis: Distribution by CPC Symbols
Figure 13.15 Novel Antibody Therapies Market: Patent Valuation
Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 14.4 Partnerships and Collaborations: Distribution by Most Popular Drug
Figure 14.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.6 Most Active Players: Distribution by Number of Partnerships
Figure 14.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 14.8 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 14.9 Partnerships and Collaborations: Distribution by Country
Figure 14.10 Partnerships and Collaborations: Distribution by Continent
Figure 15.1 Benchmarking of Big Pharma Players: Distribution by Developer Strength
Figure 15.2 Benchmarking of Big Pharma Players: Distribution by Portfolio Strength
Figure 15.3 Benchmarking of Big Pharma Players: Distribution by Portfolio Diversity
Figure 15.4 Benchmarking of Big Pharma Initiatives: Spider Web Analysis
Figure 15.5 Big Pharma Initiatives: Harvey Ball Analysis
Figure 15.6 Big Pharma Initiatives: Benchmarking: Wind Rose Chart
Figure 16.1 Market Trends and Outlook: Growth Drivers
Figure 16.2 Market Trends and Outlook: Growth Restraints
Figure 16.3 Market Trends and Outlook: Market Opportunities
Figure 16.4 Market Trends and Outlook: Market Challenges
Figure 17.1 Global Novel Antibody Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.2 Global Novel Antibody Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 17.3 Global Novel Antibody Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 18.1 Novel Antibody Therapies Market: Distribution by Drug
Figure 18.2 Novel Antibody Therapies Market for Adcetris, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.3 Novel Antibody Therapies Market for Kadcyla, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.4 Novel Antibody Therapies Market for ELZONRIS, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.5 Novel Antibody Therapies Market for Besponsa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.6 Novel Antibody Therapies Market for LYMPHIR, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.7 Novel Antibody Therapies Market for Fibromun, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.8 Novel Antibody Therapies Market for Nidlegy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.9 Novel Antibody Therapies Market for Iomab-B, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.10 Novel Antibody Therapies Market for TLX 591, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.1 Novel Antibody Therapies Market: Distribution by Type of Novel Antibody
Figure 19.2 Novel Antibody Therapies Market for Immunotoxins, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.3 Novel Antibody Therapies Market for Immunocytokines, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.4 Novel Antibody Therapies Market for Immunoconjugates, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.1 Novel Antibody Therapies Market: Distribution by Target Indication
Figure 20.2 Novel Antibody Therapies Market for HER2-Positive Breast Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.3 Novel Antibody Therapies Market for Classical Hodgkin Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.4 Novel Antibody Therapies Market for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.5 Novel Antibody Therapies Market for Previously Untreated Systemic Anaplastic Large Cell Lymphoma or CD30-expressing Peripheral T-cell Lymphomas, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.6 Novel Antibody Therapies Market for Blastic Plasmacytoid Dendritic Cell Neoplasm, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.7 Novel Antibody Therapies Market for Relapsed or Refractory Cutaneous T-cell Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.8 Novel Antibody Therapies Market for Soft Tissue Sarcoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.9 Novel Antibody Therapies Market for Locally Advanced Melanoma / Stage III B/C Melanoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.10 Novel Antibody Therapies Market for Relapsed/Refractory Acute Myeloid Leukemia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.11 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.12 Novel Antibody Therapies Market for Metastatic Castration-resistant Prostate Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.1 Novel Antibody Therapies Market: Distribution by Type of Therapy
Figure 21.2 Novel Antibody Therapies Market for Monotherapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Novel Antibody Therapies Market for Combination Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.1 Novel Antibody Therapies Market: Distribution by Route of Administration
Figure 22.2 Novel Antibody Therapies Market for Intravenous Route of Administration, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Novel Antibody Therapies Market for Intratumoral Route of Administration, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.1 Novel Antibody Therapies Market: Distribution by Key Geographical Regions
Figure 23.2 Novel Antibody Therapies Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.3 Novel Antibody Therapies Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.4 Novel Antibody Therapies Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.5 Novel Antibody Therapies Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.6 Novel Antibody Therapies Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.7 Novel Antibody Therapies Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.8 Novel Antibody Therapies Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.9 Novel Antibody Therapies Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.10 Novel Antibody Therapies Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.11 Novel Antibody Therapies Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.12 Novel Antibody Therapies Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.13 Novel Antibody Therapies Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.14 Novel Antibody Therapies Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.15 Novel Antibody Therapies Market in New Zealand, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.16 Novel Antibody Therapies Market in Middle East and Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.17 Novel Antibody Therapies Market in Egypt, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.18 Novel Antibody Therapies Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.19 Novel Antibody Therapies Market in Iraq, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.20 Novel Antibody Therapies Market in Morocco, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.21 Penetration Growth (P-G) Matrix: Key Geographical Regions
Figure 23.22 Market Movement Analysis: Key Geographical Regions
Figure 24.1 Novel Antibody Therapies Market: Distribution by Leading Players, Current Year (based on sales of therapies)
Figure 24.2 Novel Antibody Therapies Market: Distribution by Leading Players, 2035 (based on sales of therapies)

LIST OF TABLES

Table 7.1 List of Radioisotope Immunoconjugates
Table 7.2 List of Radioisotope Immunoconjugates Developers
Table 8.1 List of Immunocytokines
Table 8.2 List of Immunocytokine Developers
Table 9.1 List of Immunotoxins
Table 9.2 List of Immunotoxin Developers
Table 12.1 Novel Antibody Therapies: List of Publications, since 2020
Table 13.1 Novel Antibody Therapies: List of Published Patents
Table 14.1 Novel Antibody Therapies: List of Partnerships and Collaborations, since 2020
Table 25.1 Radioisotope Immunoconjugates: Distribution by Stage of Development
Table 25.2 Radioisotope Immunoconjugates: Distribution by Type of Therapy
Table 25.3 Radioisotope Immunoconjugates: Distribution by Dosing Frequency
Table 25.4 Radioisotope Immunoconjugates: Distribution by Route of Administration
Table 25.5 Radioisotope Immunoconjugates: Distribution by Type of Radioisotope
Table 25.6 Radioisotope Immunoconjugates: Distribution by Mode of Administration
Table 25.7 Radioisotope Immunoconjugates: Distribution by Mechanism of Action
Table 25.8 Radioisotope Immunoconjugates: Distribution by Therapeutic Area
Table 25.9 Radioisotope Immunoconjugate Developers: Distribution by Year of Establishment
Table 25.10 Radioisotope Immunoconjugate Developers: Distribution by Company Size
Table 25.11 Radioisotope Immunoconjugate Developers: Distribution by Location of Headquarters
Table 25.12 Radioisotope Immunoconjugate Developers: Distribution by Type of Developer
Table 25.13 Most Active Players: Distribution by Number of Therapies
Table 25.14 Immunocytokines: Distribution by Stage of Development
Table 25.15 Immunocytokines: Distribution by Type of Cytokine
Table 25.16 Immunocytokines: Distribution by Type of Therapy
Table 25.17 Immunocytokines: Distribution by Dosing Frequency
Table 25.18 Immunocytokines: Distribution by Mechanism of Action
Table 25.19 Immunocytokines: Distribution by Mode of Administration
Table 25.20 Immunocytokines: Distribution by Type of Antigen / Format
Table 25.21 Immunocytokines: Distribution by Route of Administration
Table 25.22 Immunocytokines: Distribution by Therapeutic Area
Table 25.23 Immunocytokine Developers: Distribution by Year of Establishment
Table 25.24 Immunocytokine Developers: Distribution by Company Size
Table 25.25 Immunocytokine Developers: Distribution by Location of Headquarters (Region)
Table 25.26 Immunocytokine Developers: Distribution by Location of Headquarters (Country)
Table 25.27 Immunocytokine Developers: Distribution by Type of Developer
Table 25.28 Most Active Players: Distribution by Number of Therapies
Table 25.29 Immunotoxin Therapies: Distribution by Stage of Development
Table 25.30 Immunotoxin Therapies: Distribution by Type of Toxin
Table 25.31 Immunotoxin Therapies: Distribution by Dosing Frequency
Table 25.32 Immunotoxin Therapies: Distribution by Type of Therapy
Table 25.33 Immunotoxin Therapies: Distribution by Mode of Administration
Table 25.34 Immunotoxin Therapies: Distribution by Type of Target
Table 25.35 Immunotoxin Therapies: Distribution by Route of Administration
Table 25.36 Immunotoxin Therapies: Distribution by Therapeutic Area
Table 25.37 Immunotoxin Developers: Distribution by Year of Establishment
Table 25.38 Immunotoxin Developers: Distribution by Developer Size
Table 25.39 Immunotoxin Developers: Distribution by Location of Headquarters (Region)
Table 25.40 Immunotoxin Developers: Distribution by Location of Headquarters (Country)
Table 25.41 Immunotoxin Developers: Distribution by Type of Developer
Table 25.42 Most Active Players: Distribution by Number of Therapies
Table 25.43 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 25.44 Clinical Trial Analysis: Distribution by Trial Status
Table 25.45 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 25.46 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 25.47 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.48 Clinical Trial Analysis: Distribution by Trial Phase
Table 25.49 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.50 Clinical Trial Analysis: Distribution by Study Design
Table 25.51 Clinical Trial Analysis: Distribution by Target Patient Population
Table 25.52 Clinical Trial Analysis: Distribution by Patient Gender
Table 25.53 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.54 Most Active Players: Distribution by Number of Registered Trials
Table 25.55 Clinical Trial Analysis: Distribution of Trials and Number of Patients Enrolled by Geography
Table 25.56 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 25.57 Publication Analysis: Distribution by Year of Publication
Table 25.58 Publication Analysis: Distribution by Type of Publication
Table 25.59 Most Popular Publisher: Distribution by Number of Publications
Table 25.60 Key Journals: Distribution by Number of Publications
Table 25.61 Publication Analysis: Distribution by Impact Factor
Table 25.62 Patent Analysis: Distribution by Publication Year
Table 25.63 Patent Analysis: Distribution by Type of Patent
Table 25.64 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year
Table 25.65 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 25.66 Patent Analysis: Distribution by Application Year
Table 25.67 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Table 25.68 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Table 25.69 Patent Analysis: Distribution by Patent Age
Table 25.70 Leading Industry Players: Distribution by Number of Patents
Table 25.71 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.72 Leading Individual Assignees: Distribution by Number of Patents
Table 25.73 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 25.74 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 25.75 Partnerships and Collaborations: Cumulative Year-wise Trend
Table 25.76 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.77 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 25.78 Partnerships and Collaborations: Distribution by Most Popular Drug
Table 25.79 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.80 Most Active Players: Distribution by Number of Partnerships
Table 25.81 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 25.82 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 25.83 Partnerships and Collaborations: Distribution by Country
Table 25.84 Partnerships and Collaborations: Distribution by Continent
Table 25.85 Global Novel Antibody Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.86 Global Novel Antibody Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 25.87 Global Novel Antibody Therapies Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 25.88 Novel Antibody Therapies Market: Distribution by Drug
Table 25.89 Novel Antibody Therapies Market for Adcetris, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.90 Novel Antibody Therapies Market for Kadcyla, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.91 Novel Antibody Therapies Market for ELZONRIS, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.92 Novel Antibody Therapies Market for Besponsa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.93 Novel Antibody Therapies Market for LYMPHIR, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.94 Novel Antibody Therapies Market for Fibromun, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.95 Novel Antibody Therapies Market for Nidlegy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.96 Novel Antibody Therapies Market for Iomab-B, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.97 Novel Antibody Therapies Market for TLX 591, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.98 Novel Antibody Therapies Market: Distribution by Type of Novel Antibody
Table 25.99 Novel Antibody Therapies Market for Immunotoxins, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.100 Novel Antibody Therapies Market for Immunocytokines, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.101 Novel Antibody Therapies Market for Immunoconjugates, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.102 Novel Antibody Therapies Market: Distribution by Target Indication
Table 25.103 Novel Antibody Therapies Market for HER2-Positive Breast Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.104 Novel Antibody Therapies Market for Classical Hodgkin Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.105 Novel Antibody Therapies Market for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.106 Novel Antibody Therapies Market for Previously Untreated Systemic Anaplastic Large Cell Lymphoma or CD30-expressing Peripheral T-cell Lymphomas, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.107 Novel Antibody Therapies Market for Blastic Plasmacytoid Dendritic Cell Neoplasm, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.108 Novel Antibody Therapies Market for Relapsed or Refractory Cutaneous T-cell Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.109 Novel Antibody Therapies Market for Soft Tissue Sarcoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.110 Novel Antibody Therapies Market for Locally Advanced Melanoma / Stage III B/C Melanoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.111 Novel Antibody Therapies Market for Relapsed/Refractory Acute Myeloid Leukemia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.112 Novel Antibody Therapies Market for Diffuse Large B-cell Lymphoma, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.113 Novel Antibody Therapies Market for Metastatic Castration-resistant Prostate Cancer, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.114 Novel Antibody Therapies Market: Distribution by Type of Therapy
Table 25.115 Novel Antibody Therapies Market for Monotherapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.116 Novel Antibody Therapies Market for Combination Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.117 Novel Antibody Therapies Market: Distribution by Route of Administration
Table 25.118 Novel Antibody Therapies Market for Intravenous Route of Administration, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.119 Novel Antibody Therapies Market for Intratumoral Route of Administration, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.120 Novel Antibody Therapies Market: Distribution by Key Geographical Regions
Table 25.121 Novel Antibody Therapies Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.122 Novel Antibody Therapies Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.123 Novel Antibody Therapies Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.124 Novel Antibody Therapies Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.125 Novel Antibody Therapies Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.126 Novel Antibody Therapies Market in the UK Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.127 Novel Antibody Therapies Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.128 Novel Antibody Therapies Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.129 Novel Antibody Therapies Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.130 Novel Antibody Therapies Market in Asia-Pacific, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.131 Novel Antibody Therapies Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.132 Novel Antibody Therapies Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.133 Novel Antibody Therapies Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.134 Novel Antibody Therapies Market in New Zealand, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.135 Novel Antibody Therapies Market in Middle East and Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.136 Novel Antibody Therapies Market in Egypt, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.137 Novel Antibody Therapies Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.138 Novel Antibody Therapies Market in Iraq, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.139 Novel Antibody Therapies Market in Morocco, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Million)
Table 25.140 Novel Antibody Therapies Market: Distribution by Leading Players, Current Year (based on sales of therapies)
Table 25.141 Novel Antibody Therapies Market: Distribution by Leading Players, 2035 (based on sales of therapies)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

2seventy bio
3P Biopharmaceuticals
AbbVie
Abdera Therapeutics
Actinium Pharmaceuticals
Active Biotech
Adium Pharma
AIkido Labs
Ajinomoto Bio-Pharma
AmMax Bio
APIM Therapeutics
ARTBIO
Astellas Pharma
AstraZeneca
AVEO Oncology
Bayer
Beijing Shenogen Pharma Group
Biocytogen
Biomedical Advanced Research and Development Authority
Bright Peak Therapeutics
Bristol Myers Squibb
Cardinal Health
CellBion
Chinook Therapeutics
Citius Pharmaceuticals
City of Hope Medical Center
Clarity Pharmaceuticals
Columbia University
Compugen
Convergent Therapeutics
Daiichi Sankyo
Defence Therapeutics
Department of Defense
Duke University
Eastern Hepatobiliary Surgery Hospital
Eckert & Ziegler
Eczacibasi Pharmaceuticals Marketing
Eli Lilly
EMD Serono (acquired by Merck KGaA)
EpicentRx
Evergreen Theragnostics
EVOQ Therapeutics
FibroGen
FUJIFILM Pharmaceuticals
Full-Life Technologies
Fusion Pharmaceuticals (acquired by AstraZeneca)
FutureGen Biopharmaceutical
Genentech
Genopharm
Gilead Sciences
Global Medical Solutions
Grand Pharma
Great Ormond Street Hospital for Children NHS Foundation Trust
GT Biopharma
Heidelberg University Hospital
Hikma Pharmaceuticals
iBio
Immatics Biotechnologies
Immedica Pharma
IONETIX
Iovance Biotherapeutics
ITM Isotope Technologies Munich
Isotopia
Janssen Biotech
Jounce Therapeutics
Kanaph Therapeutics
Kettering Health
LinqMed
Livzon MABPharm
Ludwig Institute for Cancer Research
M.D. Anderson Cancer Center
MacroGenics
Massachusetts Institute of Technology (MIT)
MedImmune
Memorial Sloan Kettering Cancer Center (MSK)
Merck
MiroBio (acquired by Gilead Sciences)
Monopar Therapeutics
Merck Sharp & Dohme (MSD)
Nammi Therapeutics
NanoMab
National Cancer Institute (NCI)
National Institutes of Health
National University of Singapore
Nektar Therapeutics
Neopharm Medical Supplies & Commerce
NIOWAVE
Nippon Shinyaku
Nordic Nanovector
Norroy Bioscience
Northstar Medical Radioisotopes
Novartis
OncoBeta
Orano
Orano Med
Orchestra Life Sciences
OSE Immunotherapeutics
Oslo University Hospital
Panacea Venture
PeptiDream
Pfizer
Philogen
POINT Biopharma (acquired by Eli Lilly)
Precirix
ProMIS Neurosciences
Qilu Pharmaceutical
Radboud University Medical Center
Radiopharm Theranostics
Regeneron Pharmaceuticals
RemeGen
Roche
Roivant Sciences
SciClone Pharmaceuticals
Seagen
SHINE Technologies
SOTIO Biotech
Stemline Therapeutics (acquired by Menarini Group)
Sumgen Biotech
Sun Pharma
Swixx BioPharma
Synaffix
Takeda Pharmaceutical
Telavant (acquired by Roche)
Telix Pharmaceuticals
Thor Medical (acquired by Nordic Nanovector)
TRIUMF
U.S. Department of Health and Human Services
Unité Chimique Belge
Ultragenyx
Uniklinik RWTH Aachen
University of California
University of Pennsylvania
University of Southampton
The University of Texas at Austin
University of Vanderbilt
Var2 Pharmaceuticals
Vybion
WEP Clinical
Xencor
Xilio Therapeutics
Y-mAbs Therapeutics

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4314EUR$4,799USD£3,744GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6291EUR$6,999USD£5,461GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16179EUR$17,999USD£14,044GBP